Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy

Zhao‐Sen Zeng; Qiuqin He; Yonghong Liang; Xiaoqing Feng; Fen‐Er Chen; De Clercq Erik; Jan Balzarini; Christophe Pannecouque

doi:10.1016/j.bmc.2010.05.081

Back

Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy

Article 2010 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2005

Synthesis, Anti-HIV Activity, and Metabolic Stability of New Alkenyldiarylmethane HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

Bo‐Liang Deng, Tracy L. Hartman, Robert W. Buckheit, Christophe Pannecouque, De Clercq Erik, Phillip E. Fanwick, Mark Cushman

Article2008

Non‐Nucleoside HIV‐1 Reverse‐Transcriptase Inhibitors. Part 10

Yueping Wang, Fen‐Er Chen, Jan Balzarini, De Clercq Erik, Christophe Pannecouque

Article2009

Non‐Nucleoside HIV‐1 Reverse Transcriptase Inhibitors. Part 13

Yuan‐Zhen Xiong, Fen‐Er Chen, Jan Balzarini, De Clercq Erik, Christophe Pannecouque

Article2017

Designing Novel Hydrazinecarbothioamides as Potential HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

Hong Yin, Zheng-Yong Wan, Ge Meng, Fen‐Er Chen, De Clercq Erik, and Christophe Pannecouque

Article2005

Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase

Juliana Ruiz‐Caro, Aravind Basavapathruni, Joseph T. Kim, Christopher M. Bailey, Ligong Wang, Karen S. Anderson, Andrew D. Hamilton, William L. Jorgensen

Bioorganic & Medicinal Chemistry Letters